SENEB BIOSCIENCES, INC.

Biotech · Private

SNB-4050, a galactosyl-ceramide analog therapeutic molecule for treating Batten disease

Grants
$449K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
0 granted · 8 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Neurotrophic Agents for Treating Parkinson's Disaese$233,804
Federal grantDepartment of Health and Human Services · Phase I · A Novel Treatment for Batten Disease$215,116
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3069Vidasym, Inc——
3070Arrowhead Pharmaceuticals——
3071XTEM PHARMACEUTICALS, INC.——
3072SENEB BIOSCIENCES, INC.——
3073Roivant Sciences——
3074ADVANCED GENETIC SYSTEMS, INC.——
3075IQ PROTEOMICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 8
  • Treatment Of GM1 Deficienciesapplication
  • Liposomal Formulations For Treatment Of GM1 Deficienciesapplication
  • Liposomal Formulations For Treatment Of GM1 Deficienciesapplication
  • Treatment Of GM1 Deficienciesapplication
  • Treatment Of GM1 Deficiencyapplication
  • Treatment Of Hypoglycemiaapplication
  • Glycolipids As Treatment For Diseaseapplication
  • Liposomal Formulations For Treatment Of GM1 Deficienciesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.